GB2553099A — Use
Assigned to Shield Tx UK Ltd · Expires 2018-02-28 · 8y expired
What this patent protects
The use of iron hydroxypyrones such as ferric trimaltol, ferric tri-hydoxypyrone or a hydroxyl-4-pyrone such as 3-hydroxy-4-pyrone in the treatment or prevention of iron deficiency in subjects having elevated hepcidin levels such as those with anaemia of chronic disease or anaemi…
USPTO Abstract
The use of iron hydroxypyrones such as ferric trimaltol, ferric tri-hydoxypyrone or a hydroxyl-4-pyrone such as 3-hydroxy-4-pyrone in the treatment or prevention of iron deficiency in subjects having elevated hepcidin levels such as those with anaemia of chronic disease or anaemia of chronic inflammation is disclosed.
Drugs covered by this patent
- Accrufer (FERRIC MALTOL) · Shield Tx
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.